$88.63
0.64% yesterday
Nasdaq, Jul 21, 10:00 pm CET
ISIN
US76243J1051
Symbol
RYTM
Sector
Industry

Rhythm Pharmaceuticals, Inc. Stock price

$88.63
+26.50 42.65% 1M
+31.11 54.09% 6M
+32.65 58.32% YTD
+38.85 78.04% 1Y
+73.88 500.88% 3Y
+66.51 300.68% 5Y
+58.63 195.43% 10Y
+58.63 195.43% 20Y
Nasdaq, Closing price Mon, Jul 21 2025
-0.57 0.64%
ISIN
US76243J1051
Symbol
RYTM
Sector
Industry

Key metrics

Basic
Market capitalization
$5.8b
Enterprise Value
$5.6b
Net debt
positive
Cash
$314.5m
Shares outstanding
63.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
35.8 | 32.8
EV/Sales
34.5 | 31.7
EV/FCF
negative
P/B
35.7
Financial Health
Equity Ratio
42.0%
Return on Equity
-160.8%
ROCE
-113.7%
ROIC
-10,030.0%
Debt/Equity
0.7
Financials (TTM | estimate)
Revenue
$162.8m | $178.9m
EBITDA
$-311.0m | $-180.0m
EBIT
$-312.5m | $-166.1m
Net Income
$-315.4m | $-179.6m
Free Cash Flow
$-113.5m
Growth (TTM | estimate)
Revenue
77.1% | 37.5%
EBITDA
-15.2% | 31.8%
EBIT
-15.0% | 37.4%
Net Income
-15.2% | 32.1%
Free Cash Flow
19.2%
Margin (TTM | estimate)
Gross
89.6%
EBITDA
-191.0% | -100.6%
EBIT
-191.9%
Net
-193.7% | -100.4%
Free Cash Flow
-69.7%
More
EPS
$-5.0
FCF per Share
$-1.8
Short interest
9.7%
Employees
283
Rev per Employee
$460.0k
Show more

Is Rhythm Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,010 stocks worldwide.

Rhythm Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Rhythm Pharmaceuticals, Inc. forecast:

17x Buy
94%
1x Hold
6%

Analyst Opinions

18 Analysts have issued a Rhythm Pharmaceuticals, Inc. forecast:

Buy
94%
Hold
6%

Financial data from Rhythm Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
163 163
77% 77%
100%
- Direct Costs 17 17
59% 59%
10%
146 146
79% 79%
90%
- Selling and Administrative Expenses 183 183
44% 44%
113%
- Research and Development Expense 275 275
22% 22%
169%
-311 -311
15% 15%
-191%
- Depreciation and Amortization 1.54 1.54
9% 9%
1%
EBIT (Operating Income) EBIT -313 -313
15% 15%
-192%
Net Profit -315 -315
15% 15%
-194%

In millions USD.

Don't miss a Thing! We will send you all news about Rhythm Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Rhythm Pharmaceuticals, Inc. Stock News

Positive
The Motley Fool
about 22 hours ago
If you're interested in capitalizing on the rapidly growing weight management market, you might naturally consider investing in Eli Lilly and Novo Nordisk. That's not a bad strategy since these two are the undisputed leaders in the field.
Neutral
The Motley Fool
4 days ago
Smith Hunter C, Chief Financial Officer of Rhythm Pharmaceuticals (RYTM -0.04%), reported mixed transactions totaling 42,120 shares on July 9, 2025, as disclosed in an SEC Form 4 filing, resulting in post-transaction holdings of 116,915 shares.
Neutral
GlobeNewsWire
10 days ago
- Presentations highlight clinically meaningful reductions in BMI in patients with acquired hypothalamic obesity – - Full data from Phase 3 TRANSCEND study underscore potential efficacy of setmelanotide, including with prior use or concomitant use of GLP-1s - BOSTON, July 12, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical compan...
More Rhythm Pharmaceuticals, Inc. News

Company Profile

Rhythm Pharmaceuticals, Inc. engages in developing and commercializing peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencies. It focuses on the treatment for Prader-Willi Syndrome and Pro-Opiomelanocortin deficiency obesity. Its product candidate includes setmelanotide, an MC4R agonist designed to restore impaired MC4R pathway function caused by genetic variants that occur upstream of the MC4R. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.

Head office United States
CEO David Meeker
Employees 283
Founded 2008
Website rhythmtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today